Targeting histone deacetylases in myeloid cells inhibits their maturation and inflammatory function with limited effects on atherosclerosis

Rosario Luque-Martin, Jan Van Den Bossche, Rebecca C. Furze, Annette E. Neele, Saskia Van Der Velden, Marion J.J. Gijbels, Cindy P.P.A. Van Roomen, Sharon G. Bernard, Wouter J. De Jonge, Inmaculada Rioja, Rab K. Prinjha, Huw D. Lewis, Palwinder K. Mander, Menno P.J. De Winther*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Monocytes and macrophages are key drivers in the pathogenesis of inflammatory diseases. Epigenetic targets have been shown to control the transcriptional profile and phenotype of these cells. Since histone deacetylase protein inhibitors demonstrate profound anti-inflammatory activity, we wanted to test whether HDAC inhibition within monocytes and macrophages could be applied to suppress inflammation in vivo. ESM technology conjugates an esterase-sensitive motif (ESM) onto small molecules to allow targeting of cells that express carboxylesterase 1 (CES1), such as mononuclear myeloid cells. This study utilized an ESM-HDAC inhibitor to target monocytes and macrophages in mice in both an acute response model and an atherosclerosis model. We demonstrate that the molecule blocks the maturation of peritoneal macrophages and inhibits pro-inflammatory cytokine production in both models but to a lesser extent in the atherosclerosis model. Despite regulating the inflammatory response, ESM-HDAC528 did not significantly affect plaque size or phenotype, although histological classification of the plaques demonstrated a significant shift to a less severe phenotype. We hereby show that HDAC inhibition in myeloid cells impairs the maturation and activation of peritoneal macrophages but shows limited efficacy in a model of atherosclerosis.

Original languageEnglish
Article number1242
JournalFrontiers in Pharmacology
Volume10
Issue numberOCT
DOIs
Publication statusPublished - 1 Jan 2019

Cite this